Zynerba Pharmaceuticals

The CIN framework assigns Zynerba Pharmaceuticals a Neutral rating at 40/100, with conviction of 3 out of 5. Fundamentals carry 35 percent of the model, regulatory posture 25, market signal 25, and editorial density 15, with every pillar contribution auditable. Regulatory leads the pillar table at 49, and is the main lever behind the Neutral conclusion. The offset comes from editorial at 30, which pulls the composite toward the middle of the band.

Under the hood, the data points sit as follows: reported revenue growth of 0.0 percent year over year, an operating margin of 0.0 percent, a market cap near 70 million. Each of those figures ties back to a specific input in the pillar breakdown. All inputs are drawn from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage density. Because every ticker in the CIN universe is scored on the same 336-name basis, Zynerba Pharmaceuticals slots into a direct comparison rather than a bespoke narrative, and the score refreshes on the primary-source ingest cadence.

Regulatory posture is where the rating breathes. That pillar contributes 49, and a step-up in filing frequency without any enforcement activity would be the cleanest catalyst for a tighter reading.